How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

35,873 results for

Plaque

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

121. Inhibition of plaque progression and promotion of plaque stability by glucagon-like peptide-1 receptor agonist: Serial in vivo findings from iMap-IVUS in Watanabe heritable hyperlipidemic rabbits. (Abstract)

Inhibition of plaque progression and promotion of plaque stability by glucagon-like peptide-1 receptor agonist: Serial in vivo findings from iMap-IVUS in Watanabe heritable hyperlipidemic rabbits. Glucagon-like peptide-1 (GLP-1) is thought to inhibit development of aortic atherosclerosis and plaque formation. However, whether GLP-1 stabilizes fully developed atherosclerotic plaque or alters the complicated plaque composition remains unclarified.Ten Watanabe heritable hyperlipidemic (WHHL (...) ) rabbits were divided into GLP-1 receptor agonist treatment group and control group. After confirmation of atherosclerotic plaques in brachiocephalic arteries by iMap intravascular ultrasound (iMAP-IVUS), GLP-1 receptor agonist lixisenatide was administered to WHHL rabbits at 30 nmoL/kg/day for 12 weeks by osmotic pump. An equal volume of normal saline was administered in a control group. After evaluation by iMAP-IVUS at 12 weeks, brachiocephalic arteries were harvested for pathological histological

2017 Atherosclerosis

122. Head-to-Head Comparison of Inflammation and Neovascularization in Human Carotid Plaques: Implications for the Imaging of Vulnerable Plaques. Full Text available with Trip Pro

Head-to-Head Comparison of Inflammation and Neovascularization in Human Carotid Plaques: Implications for the Imaging of Vulnerable Plaques. Inflammation and intraplaque neovascularization are acknowledged to be 2 features of plaque vulnerability, although their temporal expression and their respective value in predicting clinical events are poorly understood. To determine their respective temporal associations, we conducted a comprehensive assessment of inflammation and intraplaque (...) neovascularization in the carotid plaque of symptomatic and asymptomatic patients.Thirty patients with severe carotid stenosis underwent 18F-fluorodeoxyglucose-positron emission tomography/computed tomographic imaging. Plaque 18F-fluorodeoxyglucose-uptake, indicative of inflammation, was measured by calculating the target:background ratio. The presence of intraplaque neovascularization during contrast-enhanced ultrasound was judged semiquantitatively; low-grade contrast enhancement (CE) suggested its absence

2017 Circulation. Cardiovascular imaging

123. Anti-plaque and antimicrobial efficiency of different oral rinses in a 3-day plaque accumulation model. (Abstract)

Anti-plaque and antimicrobial efficiency of different oral rinses in a 3-day plaque accumulation model. The idea of incorporating a mouthrinse with normal tooth brushing could be a useful adjunct to oral hygiene. Despite the principle nature of the toothpaste vehicle, most alcohol-based chemical plaque-control agents have been evaluated and later formulated in the mouthrinse vehicle. The current study was aimed to investigate the persistence of antimicrobial action and plaque inhibitory (...) properties of a new alcohol-free mouthrinse when compared with positive control, chlorhexidine 0.12% and placebo control, physiologic saline solution mouthrinses. The evaluation of the antimicrobial activity was performed by saliva samples collected during the 3 days of usage. The results of this study indicate that this new oral rinse has an equivalent plaque inhibitory action to chlorhexidine, and the plaque inhibitory action of the rinse appears to be derived from a persistence of antimicrobial action

2017 Journal of biological regulators and homeostatic agents Controlled trial quality: uncertain

124. Optical Coherence Tomography (OCT) for plaque characterization and stent implantation

Optical Coherence Tomography (OCT) for plaque characterization and stent implantation Optical Coherence Tomography (OCT) for plaque characterization and stent implantation Optical Coherence Tomography (OCT) for plaque characterization and stent implantation HAYES, Inc. Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation HAYES, Inc.. Optical Coherence Tomography (OCT (...) ) for plaque characterization and stent implantation. Lansdale: HAYES, Inc.. Directory Publication. 2016 Authors' conclusions Purpose of Technology: Optical coherence tomography (OCT) relies on detection of reflected infrared light to generate a highly detailed, magnified view of a thin layer of tissue. This technology has been adapted to percutaneous catheters and is being used to examine features of intracoronary plaques and stents that may increase the risk of subsequent adverse events such as clot

2016 Health Technology Assessment (HTA) Database.

125. Tofacitinib for chronic plaque psoriasis - second line

Tofacitinib for chronic plaque psoriasis - second line Tofacitinib for chronic plaque psoriasis – second line Tofacitinib for chronic plaque psoriasis – second line NIHR HSRIC Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation NIHR HSRIC. Tofacitinib for chronic plaque psoriasis – second line . Birmingham: NIHR Horizon Scanning Research&Intelligence Centre. Horizon (...) Scanning Review. 2015 Authors' objectives Tofacitinib is intended to be used as second line therapy for the treatment of chronic moderate-to-severe plaque psoriasis. If licensed, it will provide an additional oral treatment option for this patient group. Tofacitinib is a novel janus kinase (JAK) inhibitor that inhibits JAK1, 2 and 3 in vitro, with functional specificity for JAK1 and 3. Inhibition of JAK1 and 3 blocks signalling of several cytokines which are required for lymphocyte activation

2015 Health Technology Assessment (HTA) Database.

126. Tildrakizumab for moderate to severe plaque psoriasis

Tildrakizumab for moderate to severe plaque psoriasis Tildrakizumab for moderate to severe plaque psoriasis Tildrakizumab for moderate to severe plaque psoriasis NIHR HSRIC Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation NIHR HSRIC. Tildrakizumab for moderate to severe plaque psoriasis. Birmingham: NIHR Horizon Scanning Research&Intelligence Centre. Horizon (...) Scanning Review. 2015 Authors' objectives Tildrakizumab is intended for use in patients with moderate to severe plaque psoriasis who have failed to respond to, have contraindications to, or are intolerant to other systemic therapies including ciclosporin, methotrexate and PUVA (psoralen ultraviolet light) therapy. If licensed, it will offer an additional treatment option for these patients who have not responded to topical or systemic therapies, and offer an alternative to other biological agents

2015 Health Technology Assessment (HTA) Database.

127. Ixekizumab for moderate to severe chronic plaque psoriasis

Ixekizumab for moderate to severe chronic plaque psoriasis Ixekizumab for moderate to severe chronic plaque psoriasis Ixekizumab for moderate to severe chronic plaque psoriasis NIHR HSRIC Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation NIHR HSRIC. Ixekizumab for moderate to severe chronic plaque psoriasis. Birmingham: NIHR Horizon Scanning Research&Intelligence (...) Centre. Horizon Scanning Review. 2015 Authors' objectives Ixekizumab is intended for the treatment of moderate to severe chronic plaque psoriasis in adults who are candidates for systemic therapy. If licensed, ixekizumab will offer an additional treatment option for this patient group. Treatment with ixekizumab may result in some patients achieving near/full clearance of psoriasis symptoms. Ixekizumab is a humanised immunoglobulin G subclass 4 (IgG4) monoclonal antibody that neutralises interleukin

2015 Health Technology Assessment (HTA) Database.

128. Targeted Immunomodulators for the Treatment of Moderate-to-Severe Plaque Psoriasis: Effectiveness and Value

Targeted Immunomodulators for the Treatment of Moderate-to-Severe Plaque Psoriasis: Effectiveness and Value ©Institute for Clinical and Economic Review, 2016 Targeted Immunomodulators for the Treatment of Moderate-to-Severe Plaque Psoriasis: Effectiveness and Value Evidence Report November 4, 2016 Prepared for ©Institute for Clinical and Economic Review, 2016 Page ii Evidence Report -Targeted Immunomodulators for the Treatment of Moderate-Severe Plaque Psoriasis Return to Table of Contents ICER (...) , 2016 Page iii Evidence Report -Targeted Immunomodulators for the Treatment of Moderate-Severe Plaque Psoriasis Return to Table of Contents Disclosure Statement: Dr. Linder owns stock in Amgen, Biogen, and Eli Lily, has contingent value rights in Sanofi Genzyme (related to alemtuzumab for multiple sclerosis); in the past 3 years, Dr. Linder has received grant support from Astellas Pharma on an unrelated topic (overactive bladder) and Clintrex, which was supported by AstraZeneca on an unrelated topic

2016 California Technology Assessment Forum

129. The Use of Aloe Vera Mouthwash in a Healthy Adult Patient Does Effectively Reduce Plaque Index

The Use of Aloe Vera Mouthwash in a Healthy Adult Patient Does Effectively Reduce Plaque Index UTCAT3070, Found CAT view, CRITICALLY APPRAISED TOPICs University: | | ORAL HEALTH EVIDENCE-BASED PRACTICE PROGRAM View the CAT / Title The Use of Aloe Vera Mouthwash in a Healthy Adult Patient Does Effectively Reduce Plaque Index Clinical Question In a healthy adult patient, does the use of Aloe Vera mouthwash effectively reduce plaque index as compared to no treatment? Clinical Bottom Line (...) For healthy adult patients, the use of Aloe Vera mouthwash effectively reduces plaque index as compared to no treatment. Aloe Vera mouthwash has proven to be an effective anti-plaque agent and can be used as a possible affordable herbal substitute for Chlorhexidine, as well as having fewer side affects. This is supported by two randomized controlled trials and is within the capability of the average general dental practice and likely to be accepted by the average patient. Best Evidence (you may view more

2016 UTHSCSA Dental School CAT Library

130. Interdental Brushes Are As Effective As Floss In Removing Interproximal Plaque

Interdental Brushes Are As Effective As Floss In Removing Interproximal Plaque UTCAT3041, Found CAT view, CRITICALLY APPRAISED TOPICs University: | | ORAL HEALTH EVIDENCE-BASED PRACTICE PROGRAM View the CAT / Title Interdental Brushes Are As Effective As Floss In Removing Interproximal Plaque Clinical Question In patients 18 years and older, are interdental brushes as effective as traditional waxed floss in reducing interproximal plaque? Clinical Bottom Line In patients 18 years and older (...) , interdental brushes are as effective as traditional floss in reducing interproximal plaque. This is supported by a meta analysis of multiple studies and a randomized controlled trial in which interdental brushes performed equally well, and in some studies better, as compared to floss by a clinically significant margin. Use of an interdental brush is easier to use and less technique sensitive for most patients and will likely result in increased use in comparison to floss. Best Evidence (you may view more

2016 UTHSCSA Dental School CAT Library

132. Smoking as a risk factor for plaque-induced oral diseases

Smoking as a risk factor for plaque-induced oral diseases Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr

2019 PROSPERO

133. Salvadora persica and its application against dental plaque control is it really beneficial? - a systematic review and meta-analysis

Salvadora persica and its application against dental plaque control is it really beneficial? - a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record

2019 PROSPERO

134. The effect of plaque control in the treatment of oral lichen planus (OLP) with gingival manifestations.

The effect of plaque control in the treatment of oral lichen planus (OLP) with gingival manifestations. Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files

2019 PROSPERO

135. The effect of lipid-lowering therapy on coronary plaque regression: a systematic review and meta-analysis

The effect of lipid-lowering therapy on coronary plaque regression: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files

2019 PROSPERO

136. Triphala mouth rinse is equally effective to chlorhexidine in the treatment of plaque-induced gingivitis: a systematic review and meta analysis

Triphala mouth rinse is equally effective to chlorhexidine in the treatment of plaque-induced gingivitis: a systematic review and meta analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2019 PROSPERO

137. Clinical efficacy of mouthwashes for dental plaque and gingival inflammation in patients undergoing orthodontic treatment: a systematic review and meta-analysis

Clinical efficacy of mouthwashes for dental plaque and gingival inflammation in patients undergoing orthodontic treatment: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2019 PROSPERO

138. Does self-ligating bracket outperform conventional bracket in plaque accumulation and gingival inflammation? A systematic review

Does self-ligating bracket outperform conventional bracket in plaque accumulation and gingival inflammation? A systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any

2019 PROSPERO

139. Carotid plaque MRI and recurrent stroke risk: a protocol for a systematic review and meta-analysis

Carotid plaque MRI and recurrent stroke risk: a protocol for a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external

2019 PROSPERO

140. Do active ingredients inhibit overnight plaque regrowth?

Do active ingredients inhibit overnight plaque regrowth? Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith

2019 PROSPERO

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>